AAN 2024: Ingrezza eases chorea, regardless of antipsychotics use
Ingrezza has been associated with sustained reductions in Huntington's chorea, regardless of concurrent antipsychotic medication use.| Huntington's Disease News
Ingrezza has been associated with sustained reductions in Huntington's chorea, regardless of concurrent antipsychotic medication use.| Huntington's Disease News
Treatment with valbenazine significantly lessened chorea motor symptoms in Huntington’s patients; an FDA submission is planned for 2022.| Huntington's Disease News
The once-daily oral therapy Ingrezza, from Neurocrine, has now been approved in the U.S. to treat chorea in adults with Huntington’s disease.| Huntington's Disease News
Marisa Wexler is a senior science writer for Huntington's Disease News with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of Huntington's disease topics.| Huntington's Disease News
Symptoms of Huntington's disease include movement disorders, psychiatric abnormalities, and cognitive and behavioral issues.| Huntington's Disease News
An oral granule formulation of Ingrezza, called Ingrezza Sprinkle, has been granted FDA approval for treating Huntington's-associated chorea.| Huntington's Disease News
Learn more about chorea, the most common involuntary movement problem in Huntington’s disease patients. Chorea usually occurs several years after disease onset.| Huntington's Disease News
Huntington's disease is a neurodegenerative disorder that can cause movement, thinking and psychiatric problems.| Huntington's Disease News
Learn about Parkinson's disease, a condition that affects the brain, resulting in issues with movement, balance, and more.| Parkinson's News Today
